1Simko F, Simko J. Heart failure and angiontensin converting enzyme inhibition: problems and prospectives[J]. Physiol Res, 1999, 48(1):1-8.
2Bristow MR. Carvedilol treatment of chronic heart failure: a new era[J]. Heart, 1998, 79(Suppl 2):8- 12.
3Michael G. Mechanism of action of beta-blocking agents in heart failure[J]. Am J Cardiol, 1997, 80(11A) :26- 32.
4Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol inthe failingheart[J]. Circulation, 1996, 94(11):2817-2825.
5Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing beta-blocking effects of carvedilol and metoprolol [J].Eur J Heart Fail, 2001, 3(3) :343-349.
6Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a beta-analysis [J]. AmHeartJ, 2001, 141(6):899-907.
7Arumanayagam M, Chan S, Tong S, et al. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial [J]. J Cardiovasc Pharmacol, 2001, 37(1):48-54.
8Bristow MR, Gilbert EM, Abrahan WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure[J].Circulation, 1996, 94(11) :2807-2816.
9Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure[J]. J Card Fail,1997, 3(3): 173-179.
10Feuerstein GZ, Bril A, Ruffolo RR. Protective effects of carvedilol in the myocardium[J]. Am J Cardiol, 1997, 80(11A) :41L- 45L.
3Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart analysis[J]. 2001,141(6): 899-907.
4Bristow MR. What type of beta- blocker should be used to treat chronic heart failure? [J].Circulation,2000,10: 484.
